Drug Profile

Research programme: protein aggregation inhibitors - Proclara Biosciences

Alternative Names: NPT-001; NPT-002 - Proclara Biosciences

Latest Information Update: 28 Dec 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator NeuroPhage Pharmaceuticals
Developer Proclara Biosciences
Class Bacteriophages
Mechanism of Action Alpha-synuclein inhibitors; Amyloid beta-protein inhibitors; Tau protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Dec 2023 Discontinued - Preclinical for Alzheimer's disease in USA (Parenteral) before December 2023
28 Dec 2023 Discontinued - Preclinical for Parkinson's disease in USA (unspecified route) before December 2023
04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (Parenteral)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com